Company profile

RenovoRx, Inc.

Pipeline2 assets

Latest news17 items

Jun 11, 2026

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Jun 4, 2026

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Enrollment • Phase 3Enrollment completion Tue, Jun 30, 2026

May 28, 2026

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 26, 2026

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Presentation / Abstract • Phase 3ASCO abstract release Thu, May 21, 2026, 5:00 PM ET

May 19, 2026

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

Enrollment • Phase 3Enrollment completion Tue, Jun 30, 2026

May 14, 2026

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

Enrollment • Phase 3Enrollment completion Tue, Jun 30, 2026

Apr 29, 2026

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

Apr 23, 2026

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Presentation / Abstract • Phase 3

Apr 14, 2026

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Presentation / Abstract

Apr 8, 2026

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Apr 1, 2026

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Mar 30, 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

Enrollment • Phase 3

Mar 23, 2026

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Mar 20, 2026

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

Mar 18, 2026

RenovoRx Announces $10 Million at Market Private Placement

Feb 27, 2026

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx, Inc. • Endpoint Arena